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A B S T R A C T
NO (nitric oxide) may be involved in fluid homoeostasis. We hypothesized that increases in NO
synthesis contribute to acute, saline-induced natriuresis, which, therefore, should be blunted when
NO availability is stabilized. Young men were studied during simultaneous infusions of L-NAME
[NG-nitro-L-arginine methyl ester; bolus of 750 μg · kg− 1 of body weight and 8.3 μg · min− 1 · kg− 1
of body weight] and SNP (sodium nitroprusside), the latter at a rate preventing L-NAME from
increasing total peripheral resistance (‘NO-clamping’). Slow volume expansion (saline, 20 μmol
of NaCl · min− 1 · kg− 1 of body weight for 3 h) was performed with and without concomitant
NO-clamping. NO-clamping itself decreased RPF (renal plasma flow; P∼ 0.02) and tended to
decrease arterial blood pressure [MABP (mean arterial blood pressure)]. Volume expansion
markedly decreased the plasma levels of renin, AngII (angiotensin II) and aldosterone (all P< 0.001),
while MABP (oscillometry), heart rate, cardiac output (impedance cardiography), RPF (by p-
aminohippurate), GFR [glomerular filtration rate; by using 51Cr-labelled EDTA] and plasma [Na+ ]
and [K+ ] remained constant. Volume expansion increased sodium excretion (P< 0.02) at constant
filtered load, but more so during NO-clamping than during control ( + 184% compared with 52%;
P< 0.0001). Urinary nitrate/nitrite excretion increased during volume expansion; plasma cGMP
and plasma vasopressin were unchanged. The results demonstrate that NO-clamping augments
sodium excretion in response to volume expansion at constant MABP and GFR, reduced RPF
and decreased renin system activity, a response termed hypernatriuresis. The results indicate that
mediator(s) other than MABP, RPF, GFR and renin system activity contribute significantly to the
homoeostatic response to saline loading, but the specific mechanisms of hypernatriuresis remain
obscure.
INTRODUCTION
Themechanisms responsible for the physiological control
of sodium balance are not clearly identified (reviewed
in [1]). After the classical experiments of Guyton and
co-workers in the 1970s [2,3], it has been widely
accepted that the RAAS (renin–angiotensin–aldosterone
system) and the pressure natriuresis mechanism are the
major determinants of normal electrolyte balance and
are pivotal to blood pressure control [4]. Nevertheless,
an increasing number of results seem to indicate that
the pressure natriuresis mechanism is not the most
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important controller of renal sodium excretion under
normal conditions. Modest sodium loading may cause
marked natriuresis without any change in arterial blood
pressure, sometimes even against minor decreases in
MABP (mean arterial blood pressure). In these situations,
changes in blood pressure cannot be the primary signal
to the kidney (reviewed in [1,5]).
Volume expansion leads to deactivation of the RAAS
and natriuresis, and the former seems to be a necessary
precondition for the latter [6]. The RAAS is believed
to be regulated by parallel inputs to renin secretion via
(i) renal arterial pressure, (ii) renal nerve activity to the
juxtaglomerular cells mediated by β1-adrenoreceptors
and (iii) the concentration of chloride in the tubular fluid
at the macula densa. The composition of the tubular
fluid at the macula densa is a complex function of
GFR (glomerular filtration rate) and proximal tubular
functions including glomerulo-tubular balance and TGF
(tubulo-glomerular feedback) [7,8]. Recent experiments
(designed to identify renal nerve activity as the primary
controller) showed unexpectedly that a large fraction of
the homoeostatic control of secretion of the RAAS may
be exerted by factors other than arterial blood pressure,
GFR and signalling via β1-adrenoreceptors [9,10]. This
unexplained control element could include the rate of
synthesis of NO. NO has multiple roles in the control
of renal function, and its actions under physiological
conditions are complex [11]. However, l-arginine [a
substrate for NOSs (nitric oxide synthases)] increases
renal bloodflow, filtration rate and sodiumexcretion [12],
whereas inhibition of NOSs reduces RPF (renal plasma
flow) and sodium excretion [13]. It seemed attractive
to hypothesize that changes in NO synthesis play an
important role in the corrective natriuresis in response
to increases in body fluid volume.
We investigated the role of NO in the renal response
to a modest sodium load proved not to affect arterial
blood pressure or GFR [1]. Simple blockade of NO
synthesis by a NOS inhibitor is unattractive because
of the associated increases in peripheral resistance and
arterial blood pressure. Therefore we combined the
administration of l-NAME (NG-nitro-l-argininemethyl
ester) with an infusion of SNP (sodium nitroprusside)
adjusted to eliminate the increase in total peripheral
resistance generated by the NOS inhibition. Under these
conditions, we performed volume expansion with iso-
osmotic saline at a modest rate. Unexpectedly, NO-
clamping did not decrease the natriuretic response to
volume expansion.
MATERIALS AND METHODS
Subjects and procedures
Nine healthy male volunteers [average age, 26 (range,
24–28) years; average height, 181 (range, 173–192) cm;
and average body weight, 81 (range, 74–88) kg] were
assigned to three separate experiments carried out in
random order with intervals of at least 2 weeks. The
subjects denied intake of any medication for 2 weeks
prior to and during the investigation. The experiments
were performed in accordance with the Declaration
of Helsinki after approval by the Danish Medicines
Agency (j. no. 2612-1988) and the regional scientific
ethical committee (ref. no. 20020035). All participants
gave written informed consent.
For 4 days prior to each experiment, the participants
ingested a standardized low-salt diet containing up to
30 mmol of Na+ ·day− 1. Compliance was checked by
analysis of urine collected during the last 24 h. In the cases
where daily excretion was higher than 40 mmol of Na+ ,
the experiment was rejected. On the day of the study, the
subjects presented at 07.50 hours having refrained from
caffeine for the last 12 h. They were weighed and seated,
and short catheters (Venflon 18G; Becton Dickinson) for
infusions and blood sampling were inserted into the left
and right superficial cubital veins respectively.
GFR was measured as the clearance of chromium-
labelled EDTA (51Cr-EDTA; GE Healthcare). An
intravenous bolus injection [27.8 kBq ·kg− 1 of body
weight) in 10 ml of 0.9% NaCl] was administered,
followed by a continuous intravenous infusion (1.04
MBq ·h− 1 in 5.5% glucose solution at 25 ml ·h− 1).
Effective RPF was measured by the clearance of PAH (p-
aminohippurate; Merck). An intravenous priming dose
of 10 mg ·kg− 1 of body weight in 10 ml of 0.9% NaCl
was administered, followed by infusion of 1.65 g ·h− 1 in
5.5% glucose solution at 25 ml ·h− 1. Clearances of PAH
and 51Cr-EDTA were calculated as the rate of excretion
divided by plasma concentration.
Electrodes for the measurement of ECG and ICG
(impedance cardiogram) were applied at the neck and
chest, and the ICG device (PhysioFlow PF-05; Manatec
Biomedical) was started. Brachial blood pressure was
measured every 10 min by the use of an automatic
oscillometric sphygmomanometer (Colin Press-Mate
BP-8800; ViCare Medical) transferring data to the ICG
apparatus. Subjects ingested 400 ml of 10% glucose
hourly.
For each subject, three investigationswere planned (for
an overview, see Figure 1): (i) infusion of iso-osmotic
NaCl solution for 3 h (n= 8; NaCl series), (ii) clamping
of the NO level by simultaneous infusion of a NOS
inhibitor and a NO donor for 5 h (n= 7; ClampCon
series) and (iii) a series of combined interventions (n= 7;
ClampNaCl series).
In the clamp series (ClampCon and ClampNaCl),
administration of l-NAME (Merck Biosciences) was
started at t= − 45 min with a priming dose of
750 μg ·kg− 1 in 10 ml of saline, followed by continuous
infusion of 8.3 μg ·min− 1 ·kg− 1 of body weight in
1 ml ·min− 1 of 5.5% glucose as described previously
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Figure 1 Time line of the experimental protocol
Prep, preparation; Bas, baseline; Inf, infusion; Rec, recovery; Mon, monitoring;
arrow with dot, blood sample; arrow with triangle, urine collection; BP, arterial
blood pressure measurements; ICG, impedance cardiography; L-NAME, L-NAME
infusion; SNP, SNP infusion. For details, see the text.
[14]. After 30 min (t= − 15 min), SNP (Abbott Labor-
atories) was added at a rate of 0.5 μg ·min− 1 ·kg− 1 of
body weight in 5.5% glucose, delivered at 5 ml ·h− 1 by
a syringe pump.
In the NaCl series (NaCl and ClampNaCl), a sodium
load of 20 μmol ·min− 1 ·kg− 1 of body weight (7.8 ml of
0.9% NaCl ·h− 1 ·kg− 1 of body weight) was given over
3 h (t= 60–240 min) by a volumetric infusion pump.
At time t= 300 min, l-NAME was withdrawn. The
infusion of SNP was stopped after an additional 30 min.
Blood and urine samples were obtained hourly. Urine
was collected by voluntary micturition; the subject was
allowed to stand during voiding if necessary.
Laboratory methods
Blood samples were centrifuged immediately at 4 ◦C.
Plasma and urine samples were analysed at the
end of the experiment by flame photometry (IL
943 Flame Photometer; Instrumentation Laboratory)
and osmometry (model 3D3; Advanced Instruments)
respectively. The activity of 51Cr in plasma and urine was
measured in a well counter (1480Wizard;Wallac). Plasma
and urine samples for the analysis of hormones, NO
metabolites [NOx (combined nitrate + nitrite)], cGMP,
PAH and creatinine were stored at − 20 ◦C.
PRC (plasma renin concentration) was assessed by the
antibody trapping method of Poulsen and Jorgensen [15]
and the activity was standardized to the World Health
Organization International Reference Reagent (Human
Renin; National Institute for Biological Standards and
Control, Potters Bar, Herts., U.K.), which was analysed
in each assay run. The results are expressed in terms of
mIU (milli-international units) · l− 1.
Concentrations of peptide hormones in plasma were
measured by RIA using specific antibodies and 125I-
labelled tracer after extraction using Sep-Pak C18
columns (Waters, Millipore, Milford, MA, U.S.A.)
[16]. Immunoreactivity of AngII (angiotensin II) in
plasma extracts was measured using the antibody Ab-
5-030682 as described previously [6] and 125I-labelled
AngII (kindly provided by Department of Clinical
Physiology, Glostrup Hospital, Glostrup, Denmark).
Vasopressin immunoreactivitywas determined by the use
of an antibody (AB3096) produced in this laboratory
[17]. The concentration of aldosterone was measured
with a commercial RIA kit (Coat-A-Count; Diagnostic
Products, Los Angeles, CA, U.S.A.).
Quantification of NOx was performed with a com-
mercial kit (850-001-KI01, Nitrate/Nitrite Colorimetric
Assaykit;CaymanChemical) by theuse of a conventional
plate reader (Elx808; Biotek Instruments).
A commercial kit (Biotrak cGMP Enzyme Immun-
oassay; GE Healthcare) was used for the determination
of concentrations of cGMP.
PAH and creatinine concentrations were determined
by conventional spectrophotometry.
Statistics
The results are presented as means+− S.E.M. Differences
between mean values at the baseline between the three
groupswere assessed by one-wayANOVAwith pairwise
comparisons based on the Tukey–Kramer method. The
development over time within each series was analysed
by a repeated measurement ANOVA using a random
intercept model with an AR(1) error structure using
PROC MIXED. Pairwise comparisons between all time
points and the baseline were made using the Tukey–
Kramer method to adjust for multiple comparisons. To
take randombaseline imbalances between the groups into
account, comparisons of the two NaCl groups are based
on dividing each measurement with the baseline value
of each individual. The comparison is then based on a
repeated measurement ANOVA of the remaining time
points using the same model as above.
In presenting our results for the single outcome
measures, we start by focusing on differences between
the baseline measurements and values obtained during or
after the infusion in each series. Thenwe report on testing
for systematic differences in the overall course between
the two NaCl series.
RESULTS
The slow saline loading was carried out under steady-
state conditions of low sodium intake. On day 4 of the
diet, baseline rates of urinary sodium excretion were
low (ClampCon: 10+− 3; ClampNaCl: 12+− 4; and NaCl:
13+− 2 mmol · 24 h− 1), while the rates of potassium
excretion were 7–10-fold higher (113+− 8, 89+− 9 and
112+− 11 mmol · 24 h− 1 in ClampCon, ClampNaCl
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Figure 2 Relative changes in renal sodium handling in the series of saline loading with and without NO-clamping
(a) Sodium excretion, (b) filtered load of sodium, (c) fractional sodium excretion and (d) GFR. , NaCl series (n = 8); , ClampNaCl series (n = 7). The results are
means+− S.E.M.; ∗significantly different from baseline value; §significantly different from the value in the first hour of infusion.
andNaCl respectively). One participant was excluded on
the basis of apparent lackof compliancewith the diet (24 h
sodium excretion rates of 48 and 42 mmol on separate
occasions). Data from eight participants are reported; six
subjects underwent all of the procedures.
Natriuretic response
The saline loading increased renal sodium excretion
(Figure 2 and Table 1). Without NO-clamping (NaCl
series), the rate of sodium excretion within the infusion
period showed a strong tendency towards an increase
when compared with the baseline (from 23+− 5 to
30+− 6 μmol ·min− 1, P∼ 0.06), and the excretion rate
after the infusion (35+− 7 μmol ·min− 1) was increased
significantly compared with the first hour of infusion
(P< 0.05). When the same saline load was administered
during NO-clamping (ClampNaCl series), there was a
robust increase in the rate of sodium excretion (from
19+− 5 to 54+− 10 μmol ·min− 1 post-infusion, P< 0.001).
Without NO-clamp, the change in sodium excretion was
approx. 50%. During NO-clamping, sodium excretion
rose by a factor of 3 (Figure 2), and the difference
between the two series is highly significant (P< 0.0001).
The baseline values of sodium excretion and of filtered
load of sodium in the two sessions were similar (Table 1).
Thus, during NO-clamping, the sodium loading elicited
a natriuretic responsemarkedly larger than thatmeasured
without clamping (Figure 2).
Other renal functions
Clamping of NO itself was associated with a decrease in
RPF (Table 1); during NO blockade, the RPF at baseline
was 24% smaller (P∼ 0.02) than the corresponding value
obtained in the absence of l-NAME (Table 1). Clamping
of NO did not change the baseline values of GFR or
filtered load of sodium (hereafter referred to as FiLoad-
Na+ ; NaCl compared with ClampNaCl and ClampCon;
see Table 1).
Neither with or without NO-blockade did the saline
loading change RPF (Table 1); there was not even a
tendency towards an increase. In addition, the FiLoad-
Na+ and the GFR remained constant during the saline
loading (Table 1 and Figure 2). Therefore changes in RPF,
GFR or FiLoad-Na+ do not appear to be involved in
the present natriuretic responses. In terms of relative
changes in GFR and FiLoad-Na+ , the data from the
clamp series showed a transient decrease during the saline
loading (ClampNaCl compared with NaCl; FiLoad-
Na+ : P< 0.02, GFR: P< 0.01, Figure 2); however, the
decrease was relatively small and occurred only during
the middle hour of infusion. In the absence of NO-
clamping, the saline loading increased the renal excretion
ofNOmetabolites (NOx) significantly (P< 0.02; Table 1)
despite a fall in the plasma concentration (see below).
The urinary excretion rate of cGMP did not change
measurably during any of the three series of experiments
(Table 1). Fractional potassium excretion increased in all
three studies in a very similar way (Table 1).
In summary, NO-clamping itself decreased RPF, but
did not change either theGFRor the FiLoad-Na+ . Saline
loading increased the rate of sodium excretion signi-
ficantly more during NO-clamping than without NO-
clamping, i.e. NO-clamping is associated with hyper-
natriuresis. Saline loading did not increase RPF, GFR or
C© The Authors Journal compilation C© 2012 Biochemical Society
NO-mediated sodium excretion in healthy young men 67
Table 1 Renal variables
Values are means+− S.E.M. NaCl was infused at 20 μmol · min− 1 · kg− 1 of body weight from t = 60 to 240 min. ∗Significantly different from the
baseline value (P < 0.05). †Significantly different from the corresponding NaCl series (only applied at the baseline; P < 0.05). §Significantly different from
the value in the first hour of infusion (P < 0.05). ClampCon, control series; NaCl, NaCl series; ClampNaCl, NaCl infusion during clamp.
Infusion period
Baseline Post infusion
Variable Time (min) . . . 0–59 60–119 120–179 180–239 240–299
RPF (ml · min− 1)
ClampCon 414+− 31† 398+− 28 347+− 11 333+− 62 363+− 18
NaCl 552+− 35 547+− 67 562+− 63 575+− 16 586+− 63
ClampNaCl 427+− 35† 405+− 18 391+− 27 431+− 21 416+− 21
GFR (ml · min− 1)
ClampCon 110+− 5 111+− 5 107+− 6 100+− 15 108+− 5
NaCl 113+− 3 115+− 4 116+− 3 114+− 5 119+− 4
ClampNaCl 116+− 7 111+− 4 106+− 9 114+− 3 112+− 4
Filtered load of sodium (mmol · min− 1)
ClampCon 14.9+− 0.7 15.0+− 0.7 14.6+− 0.8 13.5+− 2.1 14.7+− 0.6
NaCl 15.4+− 0.5 15.8+− 0.6 15.9+− 0.4 15.6+− 0.8 16.3+− 0.6
ClampNaCl 15.8+− 1.0 15.2+− 0.6 14.4+− 1.2 15.6+− 0.5 15.5+− 0.7
Sodium excretion (μmol · min− 1)
ClampCon 10+− 2 12+− 4 13+− 5 17+− 7 18+− 7
NaCl 23+− 5 24+− 5 27+− 6 30+− 6 35+− 7§
ClampNaCl 19+− 5 27+− 5 37+− 8∗ 49+− 7∗ 54+− 10∗
Fractional sodium excretion (%)
ClampCon 0.07+− 0.02 0.08+− 0.03 0.09+− 0.04 0.12+− 0.05 0.12+− 0.05
NaCl 0.15+− 0.04 0.16+− 0.04 0.17+− 0.04 0.21+− 0.04 0.23+− 0.05
ClampNaCl 0.12+− 0.03 0.18+− 0.03 0.25+− 0.05∗ 0.32+− 0.05∗ 0.35+− 0.06∗
Potassium excretion (μmol · min− 1)
ClampCon 59+− 9 60+− 10 63+− 10 60+− 12 72+− 11
NaCl 55+− 9 67+− 10 80+− 10 84+− 12 84+− 10
ClampNaCl 55+− 6 56+− 6 62+− 7 71+− 6 72+− 7
Fractional potassium excretion (%)
ClampCon 13.9+− 2.1 14.3+− 2.5 15.5+− 2.7 17.0+− 3.1∗ 18.2+− 3.0∗
NaCl 12.9+− 1.7 14.9+− 1.8∗ 17.7+− 2.0∗ 18.9+− 1.8∗ 18.4+− 1.9∗
ClampNaCl 12.5+− 1.3 13.3+− 1.5 15.4+− 1.6 16.1+− 1.4 16.7+− 1.4∗
NOx excretion (μmol · min− 1)
ClampCon 0.43+− 0.11 0.41+− 0.10 0.33+− 0.09 0.30+− 0.10 0.27+− 0.09
NaCl 0.64+− 0.08 0.74+− 0.09 0.84+− 0.07∗ 0.89+− 0.09∗ 0.82+− 0.08
ClampNaCl 0.50+− 0.12 0.52+− 0.12 0.62+− 0.10 0.73+− 0.12 0.66+− 0.08
cGMP excretion (pmol · min− 1)
ClampCon 396+− 33 395+− 31 376+− 42 369+− 83 395+− 67
NaCl 368+− 53 344+− 46 371+− 45 360+− 37 377+− 40
ClampNaCl 498+− 53 426+− 43 364+− 45 403+− 39 397+− 47
FiLoad-Na+ , either with or without NO-clamping. In
contrast, transient decreases in GFR and FiLoad-Na+
occurred during clamping. In other words, during NO-
clamping, the saline loading elicited hypernatriuresis
despite sustained suppression of RPF and despite
transient decreases in GFR and FiLoad-Na+ . This
pattern indicates that renal haemodynamic changes
cannot explain the hypernatriuresis occurring during
NO-clamping.
Hormones and other mediators
During saline loading without and with NO-clamping
(NaCl and ClampNaCl respectively), PRC, plasma
AngII and plasma aldosterone decreased simultaneously
(Table 2 and Figure 3) and to very similar extents.
Plasma AngII and aldosterone decreased by approx.
50%. During the time control protocol (ClampCon),
PRC, plasma AngII and plasma aldosterone did not
change significantly. PlasmaNOx concentrations showed
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Table 2 Plasma electrolytes, osmolality and hormones
Values are means+− S.E.M. NaCl was infused (20 μmol · min− 1 · kg− 1 of body weight) from t = 60 to 240 min. ∗Significantly different from the
baseline value (P < 0.05). ClampCon, control series; NaCl, NaCl series; ClampNaCl, NaCl infusion during clamp.
Infusion period
Baseline Post infusion
Parameter Time (min) . . . 50 110 170 230 290
PRC (mIU · l− 1)
ClampCon 68+− 11 53+− 7 53+− 9 46+− 6 50+− 10
NaCl 86+− 13 67+− 13∗ 54+− 7∗ 46+− 6∗ 50+− 8∗
ClampNaCl 64+− 9 40+− 5∗ 35+− 4∗ 31+− 4∗ 31+− 4∗
Plasma AngII (pg · ml− 1)
ClampCon 28+− 5 25+− 4 25+− 5 21+− 4 21+− 4
NaCl 35+− 7 24+− 5∗ 18+− 3∗ 17+− 2∗ 18+− 3∗
ClampNaCl 23+− 4 17+− 4∗ 12+− 2∗ 12+− 2∗ 10+− 2∗
Plasma NOx (μmol · l− 1)
ClampCon 42+− 6 41+− 6 40+− 5 40+− 6 38+− 6
NaCl 36+− 4 35+− 3 32+− 3 31+− 4 27+− 3∗
ClampNaCl 38+− 4 37+− 4 35+− 4 32+− 3∗ 30+− 3∗
Plasma cGMP (pmol · ml− 1)
ClampCon 3.1+− 0.4 2.9+− 0.3 2.8+− 0.3 3.1+− 0.3 2.8+− 0.3
NaCl 3.0+− 0.4 3.3+− 0.4 3.0+− 0.3 3.2+− 0.2 3.1+− 0.3
ClampNaCl 3.3+− 0.4 3.5+− 0.4 3.4+− 0.3 3.2+− 0.4 3.3+− 0.4
Plasma osmolality (mOsm)
ClampCon 287+− 1 286+− 1 285+− 1 285+− 2 285+− 1
NaCl 286+− 1 285+− 1 287+− 1 287+− 1 287+− 1
ClampNaCl 287+− 1 288+− 1 288+− 1 288+− 1 289+− 1
Plasma vasopressin (pg · ml− 1)
ClampCon 2.0+− 0.3 2.0+− 0.3 2.0+− 0.4 1.9+− 0.3 2.2+− 0.4
NaCl 1.3+− 0.3 1.3+− 0.3 1.1+− 0.2 1.2+− 0.2 1.4+− 0.3
ClampNaCl 1.8+− 0.3 1.7+− 0.2 1.4+− 0.2 1.4+− 0.2 1.5+− 0.2
Plasma sodium (mmol · l− 1)
ClampCon 136.3+− 0.9 135.9+− 0.7 135.8+− 0.8 136.2+− 0.8 135.6+− 1.1
NaCl 136.2+− 0.9 136.9+− 1.0 137.1+− 0.9 136.5+− 1.4 137.2+− 1.4
ClampNaCl 136.2+− 0.9 136.0+− 0.8 136.5+− 0.8 137.3+− 0.7 139.4+− 2.0
Plasma potassium (mmol · l− 1)
ClampCon 3.88+− 0.05 3.86+− 0.06 3.96+− 0.08 3.82+− 0.07 3.75+− 0.09
NaCl 3.83+− 0.08 3.90+− 0.07 3.87+− 0.08 3.84+− 0.08 3.82+− 0.07
ClampNaCl 3.81+− 0.06 3.86+− 0.11 3.87+− 0.07 3.87+− 0.07 3.85+− 0.07
a similar pattern: during the time control protocol
(ClampCon), values were almost constant around
40 μmol · l− 1. During saline loading, plasma NOx
concentrations fell by approx. 8–9 μmol · l− 1 irrespective
of NO-clamping. Plasma cGMP concentrations were
stable throughout all the experiments (Table 2). Plasma
vasopressin showed no significant differences in any
series. In summary, changes in renin system variables,
vasopressin, NO metabolites and cGMP do not seem to
be related to the hypernatriuresis.
Systemic haemodynamics
The experiments were designed to provide inhibition
of NOS by l-NAME infusion under conditions of
unaltered peripheral resistance. The results show that
this goal was achieved as total peripheral resistance
did not deviate significantly from the baseline values;
for example, the final values of peripheral resistance
in the NaCl and ClampNaCl series were 1.13+− 0.04
and 1.15+− 0.06 mmHg · s ·ml− 1 respectively (Table 3).
MABP was measured every 10 min, and the results
were averaged to hourly values. NO-clamping tended
to reduce MABP (Table 3), but the 6–9 mmHg decreases
in mean baseline values were not statistically significant.
MABP did not deviate significantly from baseline during
either of the saline loading protocols; the mean values
showed trends towards decreases (2–6 mmHg) but none
were statistically significant. A small decrease in MABP
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Table 3 Haemodynamic variables measured with sphygmomanometry and impedance cardiography
Values are means+− S.E.M. NaCl was infused at 20 μmol · min− 1 · kg− 1 of body weight from t = 60 to 239 min. ∗Significantly different from the baseline
value (P < 0.05). ClampCon, control series; NaCl, NaCl series; ClampNaCl, NaCl infusion during clamp.
Infusion period
Baseline Post infusion
Variable Time (min) . . . 0–59 60–119 120–179 180–239 240–299
MABP (mmHg)
ClampCon 87+− 3 81+− 3∗ 80+− 4∗ 82+− 3 82+− 3
NaCl 93+− 3 91+− 3 91+− 3 90+− 3 87+− 2
ClampNaCl 84+− 4 83+− 3 83+− 3 82+− 3 84+− 3
Heart rate (beats · min− 1)
ClampCon 66+− 3 66+− 3 64+− 3 63+− 3 62+− 4
NaCl 59+− 2 57+− 1 57+− 2 57+− 2 56+− 2
ClampNaCl 65+− 4 62+− 4 61+− 4 58+− 3 59+− 4
Cardiac output (l · min− 1)
ClampCon 5.8+− 0.3 5.8+− 0.3 5.9+− 0.5 5.7+− 0.4 5.8+− 0.6
NaCl 5.5+− 0.3 5.5+− 0.4 5.3+− 0.5 5.1+− 0.4 4.9+− 0.3
ClampNaCl 5.4+− 0.2 5.5+− 0.4 5.2+− 0.3 4.8+− 0.2 4.6+− 0.2
Total peripheral resistance (mmHg · s · ml− 1)
ClampCon 0.94+− 0.06 0.87+− 0.06 0.86+− 0.07 0.91+− 0.07 0.93+− 0.10
NaCl 1.04+− 0.04 1.05+− 0.06 1.08+− 0.06 1.12+− 0.06 1.13+− 0.04
ClampNaCl 0.96+− 0.04 0.95+− 0.05 0.99+− 0.06 1.07+− 0.06 1.15+− 0.06
Figure 3 Plasma aldosterone concentrations during slow
sodium loading
, NaCl series; , ClampNaCl-series; , time control with NO-clamping.
∗Significantly different from the baseline value at t = 50 min. The results are
means+− S.E.M. (n = 6 or 7).
in the time control series was significant, but transient
(− 7 mmHg, ClampCon series, first two-third of
infusion period; P< 0.05) (Table 3). Heart rates averaged
59–66 beats ·min− 1 under baseline conditions in the
different series; significant differences between or within
the series could not be detected (Table 3). Similarly, the
baseline values of cardiac output were uniform (5.4–
5.8 l ·min− 1), and the cardiac output data did not show
any differences within or between series (Table 3).
Therefore the saline loadingwas so slow that itwas unable
to produce measurable changes in MABP, heart rate and
cardiac output with or without NO-clamping.
Side effects
During NO-clamping, most participants reported some
degree of nausea and drowsiness. A total of five
sessions were terminated prematurely and thus excluded
from the data analysis. Remarkably, plasma vasopressin
concentrations, normally sensitive to nausea, were
constant during the sessions (Table 2).
In summary, under conditions of stable haemodynam-
ics, RPF, GFR and filtered sodium load, slow saline
loading induced natriuresis along with a decrease in
PRC, plasma AngII and plasma aldosterone. However,
the increase in sodium excretion in response to the
saline loading during NO-clamping (ClampNaCl) was
three to four times that occurring without clamping
(NaCl).
DISCUSSION
We hypothesized that stabilization of the systemic
supply of NO by constant infusion of l-NAME
in combination with SNP would limit the ability
of the kidneys to respond to a modest saline load.
Our results do not support this working hypothesis.
Unexpectedly, the slow saline loading produced a clearly
exaggerated natriuretic response during NO-clamping,
a hypernatriuresis, despite no concurrent changes in
arterial blood pressure, heart rate, cardiac output, RPF,
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GFR, filtered load of sodium and cGMP excretion and
despite very similar excursions in renin system activity in
plasma and plasma NOx levels. The hypernatriuresis is
remarkable also because it occurred under conditions of
constantly reduced renal blood flow and relatively low
arterial blood pressure.
The reason for the hypernatriuresis during NO-
clamping is uncertain. It is possible that increases in
the rate of NO synthesis do play an essential role in the
normal natriuretic response to an increase in total body
sodium, but that the design of the present study did not
enable us to discover this role. Alternatively, the normal
physiological adjustments of renal sodium excretion are
independent of acute changes in the rate of NO synthesis
in the kidney.
The model
NO may participate in the regulation of renal excretory
function through several pathways. An increase in
systemic NO availability decreases peripheral vascular
resistance, reduces arterial blood pressure and, in this
way, reduces sodium excretion. In contrast, increased
availability of NO in the kidney reduces renal vascular
resistance, decreases tubular sodium reabsorption and
inhibits intrarenal control mechanisms such as TGF,
thereby favouring the excretion of sodium. In humans,
NO inhibition has been found to increase blood pressure
by 7–10% concomitant with robust decreases in RPF
of 13–20% [18–20], and infusion of l-arginine, a NOS
substrate, may increase RPF, GFR and sodium excretion
in the absence of systemic haemodynamic changes [12].
It is a major advantage of the present model that the
effects of stabilizedNO availability throughout the body
are measured at arterial blood pressures very similar to
baseline.
It is evident that the intrarenal availability of
NO, affecting the vasculature, the tubular transport
and the intrarenal control systems, is not necessarily
restored quantitatively by the present co-infusion of
nitroprusside. In the kidney, nNOS (neuronal NOS) is
expressed in the efferent arteriole, in the macula densa
and in themedulla [21–23], and eNOS (endothelial NOS)
is present in the proximal tubule, the thick ascending
part of the loop of Henle, and in the collecting ducts
in addition to the vessels [22]. It is difficult to obtain
data elucidating the local tensions of NO involved in the
function of these structures. Therefore our results may
reflect circumstances where local NO levels deviate from
those of baseline, but it remains a valid assumption that
the excursions in NO availability are limited under the
present conditions.
Several studies in normal humans have shown that
acute inhibition of NO synthesis decreases renal sodium
excretion [13,24–28]. In addition, other findings may
support the notion of a regulatory role of NO.
Administration of l-arginine, a NOS substrate, increases
sodium excretion [12,29] and augments the renal response
to volume expansion [30]. From such results it can be
argued (i) that if NO is involved in the normal control of
sodium excretion, then a slow volume expansion should
increase NO production, and (ii) that stabilization of the
supply of NO, therefore, should reduce the natriuretic
response to this intervention. Although the renal effects
of experimental perturbations of NO synthesis are clear,
the role of NO in normal fluid homoeostasis has been
very difficult to assess due to the concomitant, large
changes in renal blood flow and GFR occurring during
such perturbations.
The role of NO in sodium homoeostasis is likely to
include an effect of NO on renin secretion. Although
the conclusions from multiple studies of the effect of
NOon renin secretionunder physiological conditions are
not completely unanimous, the data supporting the view
that NO stimulates renin secretion appear strong [24,31–
35]. Therefore it seems that under in vivo conditions
NO may accelerate both sodium excretion and renin
secretion, i.e. it elicits natriuresis and activates a powerful
antinatriuretic mechanism at the same time. Against this
background, it appeared attractive to try to stabilize the
systemic supply of NO and study the effects of modest
saline loading on renin levels and sodium excretion with
and without a stabilized NO supply. The variable with
which to gauge the effect of l-NAME, and therefore
to be used for adjustment of the rate of administration
of NO donor, was vascular resistance. It was assumed
that arterial blood pressure would not be an appropriate
indicator of the l-NAME effects because blood pressure
is heavily regulated by other control systems, and it
was decided, therefore, to use total peripheral resistance
as the l-NAME effect to be eliminated by administration
of the NO donor [14]. The main methodological
questions seem to be the extent of the blockade of NO
synthesis in the kidney, and the somewhat related issue
of sensitivity of the renal NOS isoforms relative to the
eNOS of the peripheral circulation determining total
peripheral resistance.
In humans, inhibition ofNOSby infusion of l-NAME
has been investigated by infusion of a wide range of
doses from 1 μg ·min− 1 ·kg− 1 of body weight [24] to
133 μg ·min− 1 ·kg− 1 of body weight [36] for periods of
30 min [24,36], 40 min [13,34,35], 60 min [37] and 90 min
[25,26]. Priming doses have not been applied in these
investigations. As the onset of the effects of even large
doses may be slow [37], and the aim of the present
study was to maintain a new steady state for hours,
we applied bolus injection plus continuous infusion
of l-NAME, quickly followed by continuous infusion of
SNP.
There is no generally accepted method for the
assessment of the systemic NOS activity. Exhaled
amounts of NO may serve as an indicator [38], but
it is not clear to what extent this reflects the NO
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involved in vascular endothelial function [39]. In the
absence of specific measures we can conclude only that
judged from the single effect of the l-NAME on the
total peripheral resistance (+ 33%; [14]), the protocol
provided substantial, but probably incomplete inhibition
of NOS activity. This leaves open the possibility that
NOS located in different renal structures may be
inhibited to different extents, but at present it is very
difficult to assess such incompleteness of inhibition,
particularly in healthy human subjects.
The hypernatriuresis
The main new finding is that the clamping of the NO
supplywas associatedwith a hypernatriuresis irrespective
of a sustained decrease in RPF, and unaltered values of
(and, if anything, decreasing trends in) arterial blood
pressure and GFR. The significant reduction in RPF
in combination with the clear trend towards reduction
in arterial blood pressure would be expected to reduce
the rate of sodium excretion. The hypernatriuresis
occurred despite these antinatriuretic conditions, and
inasmuch as the clamp-mediated changes in ‘renal
haemodynamics’ favoured antinatriuresis, the results
indicate that changes in tubular sodium reabsorption
are the most likely cause(s) of the hypernatriuresis. l-
NAME inhibits the NOSs, of which eNOS is expressed
in the renal endothelial cells and nNOS predominantly
in the macula densa cells. Both seem to be regulated
by a variety of physiological stimuli (see the review
by Kone [40]). Endogenous NO may enhance proximal
fluid reabsorption in normal human [25], but under
experimental conditions in rats it seems to promote
excretion of sodium ions and water via an effect on
medullary blood flow [41–44]. This apparent discrepancy
may be due to species-specific and/or environmental
differences. Routine daily sodium intakes in rats scale
up to very large sodium intakes in humans.
Although seeming to support the notion that the renal
haemodynamic changes cannot be responsible for the
observed effects, the present results must be interpreted
with caution. The renal medullary circulation constitutes
a minor fraction of the renal vascular bed, so that
changes in renal haemodynamics specific to the medulla
are unlikely to be detected by measurements of total
renal blood flow by the clearance methods applied in
the present study. The results of a recent study indicate
that the renal medullary circulation is indeed particularly
sensitive to changes in NO availability [45]. Interference
with the NO supply to this relatively small region may
have major effects on renal water and solute excretion
to the extent that hypertension is generated by NOS
inhibition and abrogated by infusion of excess substrate
[41–44]. Therefore the present results do not conclusively
indicate that changes in tubular reabsorption are the cause
of the observed hypernatriuresis. Changes in medullary
haemodynamics may be a plausible cause of the present
findings.
A significant secondary result, that NO-clamping did
not reverse the l-NAME-mediated decrease in RPF,
seems to indicate that the renal vascular bed is more
sensitive to NOS inhibition by l-NAME than the re-
mainder of the peripheral vasculature. Alternatively, the
results show that the amount of NO required to return
total peripheral vascular resistance to baseline is not able
to revert renal vascular resistance. Previous results have
been interpreted to indicate that in humans the renal
vascular bedmay bemore sensitive toNO inhibition than
other vascular beds [24]. The present data are compatible
with this notion, but our design did not allow a detailed
analysis of the changes in renal perfusion.
Contrary to our expectations, the present data do not
contribute significantly to a clarification of the role of
changes of NO availability in the homoeostatic response
to slow saline loading. The finding that hypernatriuresis
occurred under conditions of depressed RPF, constant
arterial pressure and changes in systemic RAAS activity
similar to those of control experiments indicates that
mechanisms other than arterial pressure and systemic
RAAS variables are important. If, in addition, it is con-
sidered unlikely that a functionally relevant increase in
medullary flow occurred under the present 24%decrease
in total RPF, then the results indicate that changes in
renal haemodynamics may not be a plausible explanation
either. The finding that, during NO-clamping, GFR
remained unchanged despite a robust decrease in RPF
and a trend towards a decrease in arterial blood pressure
is compatible with a condition of relative hyperfiltration.
This could indicate that the efficacy of the TGF was
reduced during the NO-clamping. An increase in NO
availability in the JGA(juxtaglomerular apparatus)would
inhibit TGF (for reviews, see [46,47]) and thereby
enhance a natriuretic response [48]. If the nNOS of
the macula densa were less sensitive to inhibition by l-
NAME than the eNOS of the renal endothelium, then
the level of NO in the JGA would be higher than that
in the rest of the kidney. As mentioned above, this
would most likely be associated with an increase in
renin secretion (at least locally). Therefore NO-clamping
may be associated with reduced sensitivity of the TGF,
promoting sodium excretion, and elevated (intrarenal)
RAAS activity, increasing sodium reabsorption. Itmay be
speculated that in a dynamic situation, the reduced TGF
activity leads to hypernatriuresis, but that in steady states,
the effects of the elevated (intrarenal) RAAS activity
prevail. At present, however, there is little evidence to
support this hypothesis of selective sensitivity of different
NOS isoforms to l-NAME, resulting in an imbalance
between TGF and (intrarenal) RAAS activities. Future
studies have to be designedmore specifically to clarify the
relative importance of the different renal NO signalling
mechanisms in the control of total body sodium.
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Conclusions
The present results clearly demonstrate the existence
of hypernatriuresis during NO-clamping. Although
the mechanisms remain obscure, the response is
interesting phenomenologically. It has been known for
many years, e.g. [49,50], and recently confirmed [51]
that mild, monosymptomatic, essential hypertension is
associated with hypernatriuresis. Other studies have
demonstrated reduced renal perfusion and reduced
glomerular filtration in hypertension, e.g. [52]. If NO-
clamping in normal subjects is associated with renal
hypoperfusion, hypofiltration and hypernatriuresis, and
these phenomena also are characteristics of patients with
essential hypertension, it is possible that hypertension is
associated with reduced renal NO availability. Notably,
the hypernatriuresis present during NO-clamping and
in essential hypertension may reflect abnormal NO-
mediated modulation of the TGF. During NO-clamping,
the enzyme involved in TGF regulation (nNOS, NOS1)
could be particularly sensitive to l-NAME increasing
the eNOS/nNOS activity ratio in the kidney during
clamping, and in hypertension an increase in renal afferent
arteriolar tone could be a primary element of disease
causing chronic suppression of TGF responses. It is
possible to test the hypotheses that the enzyme activity
ratio changes during NO-clamping and that renal, rather
than extrarenal, vasoconstriction is present in essential
hypertension.
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